𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

✍ Scribed by E. Bultman; C. de Haar; A. van Liere-Baron; H. Verhoog; R. L. West; E. J. Kuipers; Z. Zelinkova; C. Janneke van der Woude

Book ID
108606561
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
197 KB
Volume
35
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of adalimumab dose escalation
Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require

Adalimumab safety in global clinical tri
Adalimumab safety in global clinical trials of patients with Crohn's disease
✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr